342435-01-2

Usage

Abbreviation

CMEP

Physical state

Yellow-orange solid

Solubility

Soluble in organic solvents such as ethanol and methanol

Field of application

Medicinal chemistry and pharmaceutical research

Usage

Building block for the synthesis of various bioactive compounds

Properties

Exhibits anticonvulsant, analgesic, and anti-inflammatory properties

Potential therapeutic applications

Treating neurological disorders and pain management

Additional research

Studied for its potential role in modulating neurotransmitter signaling pathways, particularly in the context of addictive behaviors and substance abuse

Upstream product

• 108-89-4 picoline 
• 342435-00-1 4-chloro-N,3-dimethoxy-N-methylbenzamide 
• 116022-18-5 methyl 4-chloro-3-methoxybenzoate 
• 73909-16-7 2-chloro-5-methylanisole 
• 85740-98-3 4-chloro-3-methoxybenzoic acid 
• 615-74-7 2-chloro-5-methylphenol 

Downstream Products

• 1350473-75-4 4-[3-(4-chloro-3-methoxyphenyl)-1-(4-nitrophenyl)-1H-pyrazol-4-yl]pyridine 
• 1350473-76-5 4-[3-(4-chloro-3-methoxyphenyl)-1-(4-aminophenyl)-1H-pyrazol-4-yl]pyridine 
• 1350473-77-6 1-{4-[3-(4-chloro-3-methoxyphenyl)-4-(pyridin-4-yl)-1H-pyrazol-1-yl]phenyl}-3-(2,3-dichlorophenyl)urea 
• 1350473-78-7 1-{4-[3-(4-chloro-3-methoxyphenyl)-4-(pyridin-4-yl)-1H-pyrazol-1-yl]phenyl}-3-(3,4-dichlorophenyl)urea 
• 1350473-79-8 1-{4-[3-(4-chloro-3-methoxyphenyl)-4-(pyridin-4-yl)-1H-pyrazol-1-yl]phenyl}-3-(4-chloro-3-(trifluoromethyl)phenyl)urea 
• 1350473-80-1 1-{4-[3-(4-chloro-3-methoxyphenyl)-4-(pyridin-4-yl)-1H-pyrazol-1-yl]phenyl}-3-(3,5-bis(trifluoromethyl)phenyl)urea 
• 1421622-01-6 3,4-dichloro-N-{4-[3-(4-chloro-3-methoxyphenyl)-4-(pyridin-4-yl)-1H-pyrazol-1-yl]phenyl}benzamide 
• 1350473-82-3 3,5-dichloro-N-{4-[3-(4-chloro-3-methoxyphenyl)-4-(pyridin-4-yl)-1H-pyrazol-1-yl]phenyl}benzamide 
• 1350473-84-5 4-chloro-3-trifluoromethyl-N-{4-[3-(4-chloro-3-methoxyphenyl)-4-(pyridin-4-yl)-1H-pyrazol-1-yl]phenyl}benzamide 
• 1350473-86-7 3,5-bis(trifluoromethyl)-N-{4-[3-(4-chloro-3-methoxyphenyl)-4-(pyridin-4-yl)-1H-pyrazol-1-yl]phenyl}benzamide 
• 1350473-88-9 1-{4-[3-(4-chloro-3-hydroxyphenyl)-4-(pyridin-4-yl)-1H-pyrazol-1-yl]phenyl}-3-(2,3-dichlorophenyl)urea 
• 1350473-90-3 1-{4-[3-(4-chloro-3-hydroxyphenyl)-4-(pyridin-4-yl)-1H-pyrazol-1-yl]phenyl}-3-(3,4-dichlorophenyl)urea 
• 1350473-93-6 1-{4-[3-(4-chloro-3-hydroxyphenyl)-4-(pyridin-4-yl)-1H-pyrazol-1-yl]phenyl}-3-(4-chloro-3-(trifluoromethyl)phenyl)urea 
• 1350473-95-8 1-{4-[3-(4-chloro-3-hydroxyphenyl)-4-(pyridin-4-yl)-1H-pyrazol-1-yl]phenyl}-3-(3,5-bis(trifluoromethyl)phenyl)urea 

Relevant academic research and scientific papers

Evaluation of the inhibitory effects of pyridylpyrazole derivatives on lps-induced pge2 productions and nitric oxide in murine raw 264.7 macrophages

A series of thirteen triarylpyrazole analogs were investigated as inhibitors of lipopolysaccharide (LPS)-induced prostaglandin E2 (PGE2 ) and nitric oxide (NO) production in RAW 264.7 macrophages. The target compounds 1a–m have first

Design, synthesis, in vitro potent antiproliferative activity, and kinase inhibitory effects of new triarylpyrazole derivatives possessing different heterocycle terminal moieties

A new series of triarylpyrazole derivatives having different heterocycle terminal groups have been designed and synthesised. Compounds 1h–j and 1l exhibited the highest mean percentage inhibition against the 58 cancer cell lines at a concentration of 10 μ

Antiproliferative diarylpyrazole derivatives as dual inhibitors of the ERK pathway and COX-2

A series of 3,4-diarylpyrazole-1-carboxamide derivatives was designed and synthesized. A selected group of the target compounds was tested for in vitro antiproliferative activities over a panel of 60 cancer cell lines at the National Cancer Institute (NCI, Bethesda, MD, USA) at a single-dose concentration of 10 μm, and the four most active compounds 9a, 9l, 9n, and 10o were further tested in a five-dose testing mode to determine their IC50 values over the 60 cell lines. In addition, a selected group of target compounds were tested for inhibitory effect over cyclooxygenase isozymes. Compounds 9a, 9l, 9n, and 10o were also tested for MEK and ERK kinase inhibitory activity using Western blot assay. Compound 10o was selective toward melanoma cell line subpanel, and its antiproliferative activity may be attributed to selective cyclooxygenase-2 inhibition and ERK pathway inhibition.

New triarylpyrazoles as broad-spectrum anticancer agents: Design, synthesis, and biological evaluation

A new series of diarylureas and diarylamides possessing 1,3,4-triarylpyrazole scaffold was designed and synthesized. Their in vitro antiproliferative activities against NCI-60 cell line panel were tested. Most of the compounds showed strong and broad-spec

New diarylureas and diarylamides containing 1,3,4-triarylpyrazole scaffold: Synthesis, antiproliferative evaluation against melanoma cell lines, ERK kinase inhibition, and molecular docking studies

Synthesis of a new series of diarylureas and diarylamides possessing 1,3,4-triarylpyrazole scaffold is described. Their in vitro antiproliferative activities against 9 human melanoma cell lines were tested. Compounds 12, 13, 15, and 21-23 showed the highe

Design, synthesis, and antiproliferative activity of 3,4-diarylpyrazole-1- carboxamide derivatives against melanoma cell line

Synthesis of a new series of 3,4-diarylpyrazole-1-carboxamide derivatives is described. Their antiproliferative activity against A375P human melanoma cell line was tested and the effect of substituents on the diarylpyrazole scaffold was investigated. The

IMIDAZOLE DERIVATIVES AND THEIR USE AS RAF KINASE INHIBITORS

The present invention is directed to novel compounds of Formula (I) for use in the treatment of diseases, in a mammal, in which inappropriate, excessive or undesirable angiogenesis has occurred and/or where excessive Tie2 receptor activity has occurred.